Max S. Mano

8.4k total citations · 1 hit paper
109 papers, 2.6k citations indexed

About

Max S. Mano is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Max S. Mano has authored 109 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Oncology, 43 papers in Cancer Research and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Max S. Mano's work include Breast Cancer Treatment Studies (35 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Treatment and Pharmacology (23 papers). Max S. Mano is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), HER2/EGFR in Cancer Research (34 papers) and Cancer Treatment and Pharmacology (23 papers). Max S. Mano collaborates with scholars based in Brazil, Belgium and United States. Max S. Mano's co-authors include Virginie Durbecq, Evandro de Azambuja, Fátima Cardoso, Marianne Paesmans, Denis Larsimont, Ahmad Awada, Christos Sotiriou, M. Piccart-Gebhart, Gilberto de Castro and Martine Piccart and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Max S. Mano

103 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

2007 724 citations Fátima Cardoso, Max S. Mano et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Max S. Mano Brazil	22	1.5k	987	728	582	431	109	2.6k
Renaud Sabatier France	24	1.4k 0.9×	645 0.7×	675 0.9×	529 0.9×	250 0.6×	129	2.5k
B. Ojeda Spain	26	1.9k 1.3×	1.1k 1.1×	380 0.5×	388 0.7×	275 0.6×	57	2.8k
RD Gelber Switzerland	17	1.7k 1.1×	909 0.9×	485 0.7×	502 0.9×	325 0.8×	37	2.7k
Christopher Poole United Kingdom	26	1.7k 1.2×	994 1.0×	734 1.0×	522 0.9×	322 0.7×	65	3.7k
G. N. Hortobágyi United States	23	1.7k 1.2×	962 1.0×	573 0.8×	543 0.9×	311 0.7×	106	2.7k
Manon Huizing Belgium	29	2.2k 1.5×	349 0.4×	664 0.9×	457 0.8×	226 0.5×	98	3.0k
Hans‐Joachim Lück Germany	28	1.9k 1.3×	721 0.7×	395 0.5×	572 1.0×	272 0.6×	67	2.9k
Sami Diab United States	27	1.8k 1.2×	1.0k 1.0×	812 1.1×	805 1.4×	470 1.1×	74	2.8k
Haji Chalchal Canada	15	2.7k 1.9×	857 0.9×	847 1.2×	1.1k 1.8×	1.1k 2.6×	48	3.7k
Teresa Gamucci Italy	28	2.3k 1.6×	723 0.7×	827 1.1×	688 1.2×	155 0.4×	128	3.5k

Countries citing papers authored by Max S. Mano

Since Specialization

Citations

This map shows the geographic impact of Max S. Mano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max S. Mano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max S. Mano more than expected).

Fields of papers citing papers by Max S. Mano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max S. Mano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max S. Mano. The network helps show where Max S. Mano may publish in the future.

Co-authorship network of co-authors of Max S. Mano

This figure shows the co-authorship network connecting the top 25 collaborators of Max S. Mano. A scholar is included among the top collaborators of Max S. Mano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max S. Mano. Max S. Mano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mitsuyuki, Milene Corso, et al.. (2025). Disparities in cancer clinical trials among low‐ and middle‐income countries: A 20‐year analysis. Cancer. 131(21). e70067–e70067.

Reinert, Tomás, et al.. (2024). The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients. Frontiers in Oncology. 14. 1372947–1372947. 1 indexed citations

Bergerot, Cristiane Decat, et al.. (2024). Is cancer back?—psychological issues faced by survivors of breast cancer. Annals of Palliative Medicine. 13(5). 1229–1234. 1 indexed citations

Fêde, Â., et al.. (2024). Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads. Breast Cancer Targets and Therapy. Volume 16. 51–70. 10 indexed citations

Loibl, Sibylle, Chiun‐Sheng Huang, Max S. Mano, et al.. (2022). Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE. npj Breast Cancer. 8(1). 106–106. 22 indexed citations

Dienstmann, Rodrigo, Carlos H. Barrios, Tomás Reinert, et al.. (2022). Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil. JCO Global Oncology. 8(8). e2200289–e2200289. 10 indexed citations

Testa, Laura, Max S. Mano, Renata Colombo Bonadio, et al.. (2021). Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics. 76. e3146–e3146. 3 indexed citations

Mano, Max S., et al.. (2021). The Impact of Emotional Intelligence on Enhancing Women’s Leadership Competencies. International Journal of Business and Management. 16(11). 105–105. 2 indexed citations

Mano, Max S., et al.. (2021). Implementing Multidisciplinary Tumor Boards in Oncology: a Narrative Review. Future Oncology. 18(3). 375–384. 26 indexed citations

10.

Mano, Max S.. (2020). Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems. The Breast. 54. 331–334. 2 indexed citations

11.

Loibl, Sibylle, Chiun‐Sheng Huang, Max S. Mano, et al.. (2020). 96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE. Annals of Oncology. 31. S48–S48. 18 indexed citations

12.

Carvalho, Heloísa de Andrade, et al.. (2020). Takotsubo syndrome induced by brachytherapy in a patient with endocervical adenocarcinoma. Cardio-Oncology. 6(1). 30–30. 1 indexed citations

13.

Pereira, Allan Andresson Lima, et al.. (2018). Patterns of post-operative irradiation in breast cancer patients submitted to neoadjuvant chemotherapy. 28(s1). 57–57. 13 indexed citations

14.

Carvalho, Heloísa de Andrade, et al.. (2016). Effects of locoregional radiotherapy in patients with metastatic breast cancer. The Breast. 28. 73–78. 17 indexed citations

15.

Barroso‐Sousa, Romualdo, et al.. (2016). Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives. ecancermedicalscience. 10. 609–609. 28 indexed citations

16.

Gómez, Henry, Silvia P. Neciosup, C. Tosello, et al.. (2015). A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). Clinical Breast Cancer. 16(1). 38–44. 19 indexed citations

17.

Mano, Max S., David Cameron, & Richard D. Gelber. (2006). Dr. Gelber and colleagues reply [6]. New England Journal of Medicine. 354(6). 642–643.

18.

Mano, Max S., et al.. (2005). Locally advanced breast cancer in octogenarian women. Breast Cancer Research and Treatment. 89(1). 81–90. 6 indexed citations

19.

Mano, Max S., Ahmad Awada, Angelo Di Leo, et al.. (2004). Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecologic Oncology. 92(3). 887–895. 42 indexed citations

20.

Bernard-Marty, Chantal, Max S. Mano, Marianne Paesmans, et al.. (2003). Second malignancies following adjuvant chemotherapy:6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment ofnode-positive breast cancer patients. Annals of Oncology. 14(5). 693–698. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact